Triple-negative breast cancer trials in United Kingdom

In United Kingdom 26 Also abroad 425

26 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Where
Birmingham, Cardiff, Leeds, London, Nottingham, Taunton, Truro
Age
18 years and over
People
1,000 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06841354 · EU 2024-516834-36-00
Phase 3Taking people
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Where
Blackpool, Colchester, Dundee, Huddersfield, Leicester, London, Nottingham, Orpington
Age
18 years and over
People
2,400 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06966700 · EU 2024-520190-12-00
Phase 1/2Taking people
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Where
Glasgow, London
Age
18 years and over
People
1,132 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT03424005 · EU 2023-503629-20-00
Phase 3Taking people
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Where
Bristol, Edinburgh, Hills Road, Leeds, London, Truro
Age
18 years and over
People
1,530 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06393374 · EU 2023-504962-52-00
Phase 3Taking people
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Where
Cottingham, Edgbaston, Liverpool, London, Manchester, Northwood, Taunton, York
Age
18 years and over
People
1,514 worldwide
Run by
Gilead Sciences
See details and how to joinNCT05633654 · EU 2024-512279-10-00
Phase 1Taking people
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Where
London, Manchester
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00
Phase 1Taking people
Study of XB010 in Subjects With Solid Tumors
Where
Leicester, London, Manchester
Age
18 years and over
People
396 worldwide
Run by
Exelixis
See details and how to joinNCT06545331
Phase 3Taking people
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Where
Brighton, Bristol, Cottingham, Edinburgh, Leeds, London, Oxford, Rhyl, Southampton, Stoke-on-Trent, Torquay, Wolverhampton
Age
18 years and over
People
558 worldwide
Run by
BioNTech SE
See details and how to joinNCT07173751 · EU 2025-521884-12-00
Phase 1/2Taking people
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Where
London, Newcastle upon Tyne
Age
12 years and over
People
300 worldwide
Run by
PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750
Phase 3Taking people
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Where
Cardiff, Chelsea, Leicester, Liverpool, London, Oxford, Surrey, Sutton, Taunton
Age
18 years and over
People
625 worldwide
Run by
AstraZeneca
See details and how to joinNCT06103864
Phase 1/2Taking people
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Where
Birmingham, Glasgow, London, Newcastle upon Tyne
Age
18 years and over
People
416 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06618287
Phase 1/2Taking people
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Where
Glasgow, London, Manchester, Newcastle upon Tyne, Oxford
Age
18 years and over
People
230 worldwide
Run by
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
See details and how to joinNCT05985655
Phase 1/2Taking people
TT-702 in Patients With Advanced Solid Tumours.
Where
London, Manchester, Southampton
Age
16 years and over
People
60
Run by
Cancer Research UK
See details and how to joinNCT05272709
Phase 2/3Taking people
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Where
Belfast, London, Manchester, Nottingham, Truro
Age
18 years and over
People
600 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06926868 · EU 2024-519871-24-00
Phase 1Taking people
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Where
London, Sutton
Age
18 years and over
People
714 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00
Phase 1/2Taking people
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Where
Belfast, Cardiff, Glasgow, London, Manchester, Northwood, Preston, Sutton
Age
18 years and over
People
182 worldwide
Run by
Eisai Inc.
See details and how to joinNCT04300556 · EU 2023-506868-14-00
Phase 2Taking people
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
Where
London
Age
18 years to 64 years
People
140 worldwide
Run by
Queen Mary University of London
See details and how to joinNCT06954480 · EU 2024-519913-76-00
Phase 1/2Taking people
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Where
London, Manchester, Newcastle upon Tyne, Southampton
Age
18 years and over
People
167
Run by
Cancer Research UK
See details and how to joinNCT06380816
No phaseNot yet taking people in United Kingdom
Diet-drive Gut Microbiome and Outcome in Patients With Early-stage Triple-negative Breast Cancer Undergoing Neoadjuvant Chemotherapy and Immunotherapy.
Where
London
Age
18 years and over
People
300
Run by
Barts & The London NHS Trust
See details and how to joinNCT07551765
No phaseTaking people
Breast Cancer Evolution During Neoadjuvant Systemic Therapy
Where
London
Age
18 years and over
People
500
Run by
Royal Marsden NHS Foundation Trust
See details and how to joinNCT06681064
Phase 1Taking people
A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
Where
Bristol, Edinburgh, Leeds, London, Southampton
Age
18 years and over
People
45
Run by
Epsilogen Ltd
See details and how to joinNCT06547840
No phaseTaking people
Feasibility of Serial Multisite Image-guided Biopsy to Study Breast Cancer Evolution
Where
London
Age
18 years and over
People
200
Run by
Royal Marsden NHS Foundation Trust
See details and how to joinNCT07084571
Phase 1/2Taking people
Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer
Where
Belfast, Brighton, Cambridge, Cardiff, Edinburgh, Guildford, Liverpool, London, Manchester, Nottingham, Preston, Sheffield, Sutton, Torquay
Age
18 years and over
People
168
Run by
Scancell Ltd
See details and how to joinNCT05329532
Phase 1Taking people
A Study of NX-1607 in Adults With Advanced Malignancies
Where
Cambridge, Glasgow, London, Manchester, Newcastle, Oxford, Sutton
Age
18 years and over
People
345 worldwide
Run by
Nurix Therapeutics, Inc.
See details and how to joinNCT05107674
Phase 2Taking people
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer
Where
Bournemouth, Cardiff, London, Manchester, Sheffield
Age
18 years and over
People
119
Run by
Institute of Cancer Research, United Kingdom
See details and how to joinNCT03740893